1.	Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2. Phase: Phase IV Type: Natural history/Epidemiology Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A6181203, DARENCA STUDY 2, NCT01339962
2.	RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib Phase: Phase III Type: Treatment Status: Completed Age: 18 to 90 Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001C2240, 2006-002070-21, NCT00410124
3.	Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001C2325, NCT00412061
4.	Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001C2324, EudraCT 2006-006819-75, NCT00510068
5.	A Phase III Trials Program Exploring the Integration of Bevacizumab, Everolimus (RAD001), and Lapatinib Into Current Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer Phase: Phase III Type: Genetics, Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: GBG 44, EudraCT No.: 2006-005834-19, NCT00567554
6.	Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1) Phase: Phase III Type: Treatment Status: Closed Age: Any age Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001M2301, 2007-006997-27, NCT00789828
7.	Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001M2302, 2008-002113-48, NCT00790400
8.	Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001Y2301, 2008-008698-69, NCT00863655
9.	Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001J2301, 2008-006556-21, NCT00876395
10.	Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC) Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001R2301, 2008-006544-20, NCT00879333
11.	Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001W2301, 2008-008697-31, NCT01007942
12.	Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma. Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001O2301, 2009-010196-25, NCT01035229
13.	Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-02603, CALGB 90802, U10CA031946, NCT01198158
14.	RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma Phase: Phase II, Phase I Type: Treatment Status: Completed Age: Not specified Sponsor: Other Protocol IDs: 2003-0948, NCT00081874
15.	Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer Phase: Phase II, Phase I Type: Treatment Status: Completed Age: Over 18 Sponsor: NCI, Other Protocol IDs: 04-010, MSKCC-04010, NCT00085566
16.	Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: NOVARTIS-CRAD001C2207, RPCI-PH-24204, CDR0000389252, NCI-2010-00894, NCT00093639
17.	Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: 04-033, MSKCC-04033, NCT00096486
18.	Phase I/II Study of AEE788 and Everolimus in Patients With Recurrent or Relapsed Glioblastoma Multiforme Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0409004-01, NOVARTIS-CAEE788A2106, NCT00107237
19.	Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: 2005-0471, NCT00317720
20.	Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: SCRI GU 44, CRAD001C2480, NCT00392821
21.	Phase I/II Trial of RAD001 Plus Docetaxel in Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 1342-2004, NCT00406276
22.	Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 3 and over Sponsor: Other Protocol IDs: CCHMC IRB# 06-07-50, NCT00411619
23.	Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer Phase: Phase II, Phase I Type: Treatment Status: Completed Age: Over 18 Sponsor: Other Protocol IDs: RCC-06-102, 1006-0152, NCT00448149
24.	RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 to 65 Sponsor: Other Protocol IDs: CCHMC IRB #2008-0812(04-07-22), NCT00457964
25.	The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 05-184, NCT00459186